82 related articles for article (PubMed ID: 38666914)
1. Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells.
Grundy M; Balakrishnan S; Fox M; Seedhouse CH; Russell NH
Oncotarget; 2018 Dec; 9(102):37777-37789. PubMed ID: 30701031
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.
Arai S; Jonas O; Whitman MA; Corey E; Balk SP; Chen S
Clin Cancer Res; 2018 Nov; 24(21):5458-5470. PubMed ID: 30021909
[No Abstract] [Full Text] [Related]
3. Anlotinib synergizes with venetoclax to induce mitotic catastrophe in acute myeloid leukemia.
Wang D; He J; Liu S; Zhang H; Tang D; Chen P; Yang M
Cancer Lett; 2024 Jul; 593():216970. PubMed ID: 38763475
[TBL] [Abstract][Full Text] [Related]
4. BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL.
Bauer K; Hauswirth A; Gleixner KV; Greiner G; Thaler J; Bettelheim P; Filik Y; Koller E; Hoermann G; Staber PB; Sperr WR; Keil F; Valent P
Am J Hematol; 2024 Jun; ():. PubMed ID: 38822666
[TBL] [Abstract][Full Text] [Related]
5. Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.
Montalban-Bravo G; Thongon N; Rodriguez-Sevilla JJ; Ma F; Ganan-Gomez I; Yang H; Kim YJ; Adema V; Wildeman B; Tanaka T; Darbaniyan F; Al-Atrash G; Dwyer K; Loghavi S; Kanagal-Shamanna R; Song X; Zhang J; Takahashi K; Kantarjian H; Garcia-Manero G; Colla S
Cell Rep Med; 2024 May; ():101585. PubMed ID: 38781960
[TBL] [Abstract][Full Text] [Related]
6. Combination fedratinib and venetoclax has activity against human B-ALL with high FLT3 expression.
Rinella SP; Bell HC; Hess NJ; Hoang NM; Nguyen TT; Turicek DP; Shi L; Rui L; LaBelle JL; Capitini CM
bioRxiv; 2024 May; ():. PubMed ID: 37333339
[TBL] [Abstract][Full Text] [Related]
7. Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in
Montalban-Bravo G; Ma F; Thongon N; Yang H; Gomez IG; Rodriguez-Sevilla JJ; Adema V; Wildeman B; Lockyer P; Kim YJ; Tanaka T; Darbaniyan F; Pancholy S; Zhang G; Al-Atrash G; Dwyer K; Takahashi K; Garcia-Manero G; Kantarjian H; Colla S
bioRxiv; 2023 Apr; ():. PubMed ID: 37066354
[No Abstract] [Full Text] [Related]
8. Targeting a lineage-specific PI3Kɣ-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule.
Kelly LM; Rutter JC; Lin KH; Ling F; Duchmann M; Latour E; Arang N; Pasquer H; Ho Nhat D; Charles J; Killarney ST; Ang HX; Namor F; Culeux C; Lombard B; Loew D; Swaney DL; Krogan NJ; Brunel L; Carretero É; Verdié P; Amblard M; Fodil S; Huynh T; Sebert M; Adès L; Raffoux E; Fenouille N; Itzykson R; Lobry C; Benajiba L; Forget A; Martin AR; Wood KC; Puissant A
Nat Cancer; 2024 May; ():. PubMed ID: 38816660
[TBL] [Abstract][Full Text] [Related]
9. The epichaperome: the power of many as the power of one.
Tai W; Guzman ML; Chiosis G
Oncoscience; 2016; 3(9-10):266-267. PubMed ID: 28050576
[No Abstract] [Full Text] [Related]
10. BH3 Mimetics in Hematologic Malignancies.
Klener P; Sovilj D; Renesova N; Andera L
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576319
[TBL] [Abstract][Full Text] [Related]
11. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
12. FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
Seipel K; Mandhair H; Bacher U; Pabst T
Curr Issues Mol Biol; 2024 Mar; 46(4):2946-2960. PubMed ID: 38666914
[TBL] [Abstract][Full Text] [Related]
13. HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia.
Seipel K; Kohler S; Bacher U; Pabst T
Curr Issues Mol Biol; 2023 Aug; 45(9):7011-7026. PubMed ID: 37754227
[TBL] [Abstract][Full Text] [Related]
14. Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.
Seipel K; Graber C; Flückiger L; Bacher U; Pabst T
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360855
[TBL] [Abstract][Full Text] [Related]
15. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
